Chronic Lymphocytic Leukemia (CLL) Monitoring Measurable/Minimal Residual Disease Detection, Flow Cytometry, Varies
Use
The test is useful for confirming the presence or absence of measurable (minimal) residual disease in patients with known chronic lymphocytic leukemia (CLL) who are either post-chemo/immunotherapy or post-bone marrow transplant. It provides critical prognostic information for patients who have completed therapy, assessing their disease status and potentially guiding further treatment decisions.
Special Instructions
The preferred test for evaluating any tissue biopsy for a potential lymphoproliferative disorder is LLPT / Leukemia/Lymphoma Immunophenotyping, Flow Cytometry, Tissue. For a first-time evaluation of a patient with lymphocytosis, a routine flow cytometric assay is recommended. If cytogenetic tests are requested in addition to this test, an additional specimen tube should be submitted.
Limitations
This test is only appropriate for patients with a confirmed diagnosis of chronic lymphocytic leukemia. Careful specimen handling and processing is crucial as improper specimen collection can lead to diagnostic errors. The test detects residual disease at a sensitivity of 0.002% but is not designed to replace initial diagnostic assays for CLL.
New York Approved
Methodology
Cell-based / Cytometry (Flow Cytometry)
Biomarkers
LOINC Codes
- 22637-3
- 30954-2
- 22635-7
Result Turnaround Time
1-4 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
6 mL
Minimum Volume
1 mL
Container
Yellow top (ACD solution A or B) or Lavender top (EDTA)
Collection Instructions
Send whole blood specimen in original tube. Do not aliquot. Label specimen as blood.
Causes for Rejection
Gross hemolysis, fully clotted whole blood
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 4 days |
| Refrigerated | 4 days |